Symbollon Pharmaceuticals Completes Phase III Pivotal Trial For IoGen

Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) announced the completion of its IoGen? Phase III pivotal trial. The study, conducted by physicians throughout the U.S., is designed to evaluate the effectiveness of IoGen, a treatment which may be the first FDA-approved, non-hormonal therapy for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD).

More: continued here

Filed under: Pain / Anesthetics on February 11th, 2008